Nasal Colivelin treatment ameliorates memory impairment related to Alzheimer's disease

Neuropsychopharmacology

Volumn 33, Issue 8, 2008, Pages 2020-2032

  Yamada, Marina ^a   Chiba, Tomohiro ^a   Sasabe, Jumpei ^a   Terashita, Kenzo ^a   Aiso, Sadakazu ^a   Matsuoka, Masaaki ^a  

^a KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Activity dependent neurotrophic factor; Alzheimer's disease; Colivelin; Humanin; Memory impairment

Indexed keywords

ACETYLCHOLINESTERASE; ACTIVITY DEPENDENT NEUROTROPHIC FACTOR; AMYLOID BETA PROTEIN[25-35]; CHOLINE ACETYLTRANSFERASE; COLIVELIN; DONEPEZIL; HUMANIN; MESSENGER RNA; PROLYLALANYLGLYCYLALANYLSERYLARGINYLLEUCYLLEUCYLLEUCYLLEUCYLTHREONYLGLYCYLGLUTAMYLISOLEUCYLASPARTYLLEUCYLPROLINAMIDE; SCOPOLAMINE; STAT3 PROTEIN; TACRINE; VESICULAR ACETYLCHOLINE TRANSPORTER;

ALZHEIMER DISEASE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL COUNT; CENTRAL NERVOUS SYSTEM; CHOLINERGIC TRANSMISSION; CONTROLLED STUDY; DOSE RESPONSE; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG MECHANISM; DRUG TRANSPORT; HIPPOCAMPUS; MALE; MAZE TEST; MEMORY DISORDER; MOUSE; NERVE CELL; NEUROPROTECTION; NONHUMAN; OLFACTORY BULB; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SPATIAL MEMORY; TRANSCRIPTION REGULATION; UPREGULATION; WORKING MEMORY;

ACETYLCHOLINESTERASE; ADMINISTRATION, INTRANASAL; ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; ANIMALS; BEHAVIOR, ANIMAL; CHOLINERGIC ANTAGONISTS; IMMUNOHISTOCHEMISTRY; INJECTIONS, INTRAVENTRICULAR; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MAZE LEARNING; MEMORY DISORDERS; MICE; MICE, INBRED ICR; MUSCARINIC ANTAGONISTS; OLFACTORY BULB; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SCOPOLAMINE; STAT3 TRANSCRIPTION FACTOR; UP-REGULATION;

EID: 45149115313     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.npp.1301591     Document Type: Article

References (40)

1. Bales KR, Tzavara ET, Wu S, Wade MR, Bymaster FP, Paul SM et al (2006). Cholinergic dysfunction in a mouse model of Alzheimer disease is reversed by an anti-A beta antibody. J Clin Invest 116: 825-832.
2. Balin BJ, Broadwell RD, Salcman M, El-Kalliny M (1986). Avenues for entry of peripherally administered protein to the central nervous system in mouse, rat, and squirrel monkey. J Comp Neurol 251: 260-280.
3. Bartus R, Dean III RL, Beer B, Lippa AS (1982). The cholinergic hypothesis of geriatric memory dysfunction. Science 217: 408-417.
4. Benedict C, Hallschmid M, Hatke A, Schultes B, Fehm HL, Born J et al (2004). Intranasal insulin improves memory in humans. Psychoneuroendocrinology 29: 1326-1334.
5. Brenneman DE, Gozes I (1996). A femtomolar-acting neuroprotective peptide. J Clin Invest 97: 2299-2307.
6. Brenneman DE, Hauser J, Neale E, Rubinraut S, Fridkin M, Davidson A et al (1998). Activity-dependent neurotrophic factor: structure-activity relationships of femtomolar-acting peptides. J Pharmacol Exp Ther 285: 619-627.
7. Broadwell RD, Balin BJ (1985). Endocytic and exocytic pathways of the neuronal secretory process and trans-synaptic transfer of wheat germ agglutinin-horseradish peroxidase in vivo. J Comp Neurol 242: 632-650.
8. Caccamo A, Oddo S, Billings LM, Green KN, Martinez-Coria H, Fisher A et al (2006). M1 receptors play a central role in modulating AD-like pathology in transgenic mice. Neuron 49: 671-682.
9. Cheema SS, Arumugam D, Murray SS, Bartlett PF (1998). Leukemia inhibitory factor maintains choline acetyltransferase expression in vivo. Neuroreport 9: 363-366.
10. Chiba T, Hashimoto Y, Tajima H, Yamada M, Kato R, Niikura T et al (2004). Neuroprotective effect of activity-dependent neurotrophic factor against toxicity from familial amyotrophic lateral sclerosis-linked mutant SOD1 in vitro and in vivo. J Neurosci Res 78: 542-552.
11. Chiba T, Yamada M, Hashimoto Y, Sato M, Sasabe J, Kita Y et al (2005). Development of a femtomolar-acting humanin derivative named colivelin by attaching activity-dependent neurotrophic factor to its N terminus: characterization of colivelin-mediated neuroprotection against Alzheimer's disease-relevant insults in vitro and in vivo. J Neurosci 25: 10252-10261.
12. Chiba T, Yamada M, Sasabe J, Terashita K, Aiso S, Matsuoka M et al (2006). Colivelin prolongs survival of an ALS model mouse. Biochem Biophys Res Commun 343: 793-798.
13. Coyle JT, Price DL, DeLong MR (1983). Alzheimer's disease: a disorder of cortical cholinergic innervation. Science 216: 1184-1190.
14. Fisher A, Brandeis R, Pittel Z, Karton I, Sapir M, Dachir S et al (1989). (+)-cis-2-methyl-spiro(1,3-oxathiolane-5,3′) quinuclidine (AF102B): a new M1 agonist attenuates cognitive dysfunctions in AF64A-treated rats. Neurosci Lett 102: 325-331.
15. Gozes I, Bardea A, Reshef A, Zamostiano R, Zhukovsky S, Rubinraut S et al (1996). Neuroprotective strategy for Alzheimer disease: intranasal administration of a fatty neuropeptide. Proc Natl Acad Sci USA 93: 427-432.
16. Gozes I, Giladi E, Pinhasov A, Bardea A, Brenneman DE (2000). Activity-dependent neurotrophic factor: intranasal administration of femtomolar-acting peptides improve performance in a water maze. J Pharmacol Exp Ther 293: 1091-1098.
17. Hashimoto Y, Niikura T, Ito Y, Sudo H, Hata M, Arakawa E et al (2001a). Detailed characterization of neuroprotection by a rescue factor humanin against various Alzheimer's disease-relevant insults. J Neurosci 21: 9235-9245.
18. Hashimoto Y, Niikura T, Tajima H, Yasukawa T, Sudo H, Ito Y et al (2001b). A rescue factor abolishing neuronal cell death by a wide spectrum of familial Alzheimer's disease genes and Aβ. Proc Natl Acad Sci USA 98: 6336-6341.[Erratum in: Proc Natl Acad Sci USA 98: 12854, 2001].
19. Hashimoto Y, Suzuki H, Aiso S, Niikura T, Nishimoto I, Matsuoka M (2005). Involvement of tyrosine kinases and STAT3 in humanin-mediated neuroprotection. Life Sci 77: 3092-3104.
20. Holtser-Cochav M, Divinski I, Gozes I (2006). Tubulin is the target binding site for NAP-related peptides: ADNF-9, D-NAP, and D-SAL. J Mol Neurosci 28: 303-307.
21. Illum L (2000). Transport of drugs from the nasal cavity to the central nervous system. Eur J Pharm Sci 11: 1-18.
22. Itoh J, Nabeshima T, Kameyama T (1991). Utility of an elevated plus-maze for dissociation of amnesic and behavioral effects of drugs in mice. Eur J Pharmacol 194: 71-76.
23. Jhoo JH, Kim HC, Nabeshima T, Yamada K, Shin EJ, Jhoo WK et al (2004). Beta-amyloid (1-42)-induced learning and memory deficits in mice: involvement of oxidative burdens in the hippocampus and cerebral cortex. Behav Brain Res 155: 185-196.
24. Kawasumi M, Chiba T, Yamada M, Miyamae-Kaneko M, Matsuoka M, Nakahara J et al (2004). Targeted introduction of V642I mutation in amyloid precursor protein gene causes functional abnormality resembling early stage of Alzheimer's disease in aged mice. Eur J Neurosci 19: 2826-2838.
25. Krejcova G, Patocka J, Slaninova J (2004). Effect of humanin analogues on experimentally induced impairment of spatial memory in rats. J Pept Sci 10: 636-639.
26. Lane RM, Kivipelto M, Greig NH (2004). Acetylcholinesterase and its inhibition in Alzheimer disease. Clin Neuropharmacol 27: 141-149.
27. Mamiya T, Ukai M (2001). [Gly(14)]-Humanin improved the learning and memory impairment induced by scopolamine in vivo. Br J Pharmacol 134: 1597-1599.
28. Matsuoka M, Hashimoto Y, Aiso S, Nishimoto I (2006). Humanin and colivelin: neuronal-death-suppressing peptides for Alzheimer's disease and amyotrophic lateral sclerosis. CNS Drug Rev 12: 113-122.
29. Mattson M (2004). Pathways towards and away from Alzheimer's disease. Nature 430: 631-639.
30. Maurice T, Lockhart BP, Privat A (1996). Amnesia induced in mice by centrally administered beta-amyloid peptides involves cholinergic dysfunction. Brain Res 706: 181-193.
31. Nishimoto I, Matsuoka M, Niikura T (2004). Unravelling the role of humanin. Trends Mol Med 10: 102-105.
32. Oda Y (1999). Choline acetyltransferase: the structure, distribution and pathologic changes in the central nervous system. Pathol Int 49: 921-937.
33. Petersen RC, Thomas RG, Grundman M, Bennett D, Doody R, Ferris S et al (2005). Vitamin E and donepezil for the treatment of mild cognitive impairment. N Engl J Med 352: 2379-2388.
34. Rogaev EI, Sherrington R, Wu C, Levesque G, Liang Y, Rogaeva EA et al (1997). Analysis of the 5′ sequence, genomic structure, and alternative splicing of the presenilin-1 gene (PSEN1) associated with early onset Alzheimer disease. Genomics 40: 415-424.
35. Tajima H, Niikura T, Hashimoto Y, Ito Y, Kita Y, Terashita K et al (2002). Evidence for in vivo production of humanin peptide, a neuroprotective factor against Alzheimer's disease-related insults. Neurosci Lett 324: 227-231.
36. Takasugi N, Tomita T, Hayashi I, Tsuruoka M, Niimura M, Takahashi Y et al (2003). The role of presenilin cofactors in the gamma-secretase complex. Nature 422: 438-441.
37. Thorne RG, Pronk GJ, Padmanabhan V, Frey II WH (2004). Delivery of insulin-like growth factor-I to the rat brain and spinal cord along olfactory and trigeminal pathways following intranasal administration. Neuroscience 127: 481-496.
38. Winblad B, Kilander L, Eriksson S, Minthon L, Batsman S, Wetterholm AL, et al, Severe Alzheimer's Disease Study Group (2006). Donepezil in patients with severe Alzheimer's disease: double-blind, parallel-group, placebo-controlled study. Lancet 367: 1057-1065.
39. Yamada K, Tanaka T, Mamiya T, Shiotani T, Kameyama T, Nabeshima T (1999). Improvement by nefiracetam of β-amyloid-(1-42)-induced learning and memory impairments in rats. Br J Pharmacol 126: 235-244.
40. Yamada M, Chiba T, Sasabe J, Nawa M, Tajima H, Niikura T et al (2005). Implanted cannula-mediated repetitive administration of Abeta25-35 into the mouse cerebral ventricle effectively impairs spatial working memory. Behav Brain Res 164: 139-146.